Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure

Jeremie H. Estepp*, Paweł Wiczling, Joseph Moen, Guolian Kang, Joana Marie Mack, Robert Liem, Julie A. Panepinto, Uttam Garg, Gregory Kearns, Kathleen A. Neville

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: The purposes of this work were to: (1) compare pharmacokinetic (PK) parameters for hydroxycarbamide in children receiving their first dose (HCnew) vs. those receiving chronic therapy (HCchronic), (2) assess the external validity of a published PK dosing strategy, and (3) explore the accuracy of dosing strategies based on a limited number of HC measurements. Methods: Utilizing data from two prospective, multicenter trials of hydroxycarbamide (Pharmacokinetics of Liquid Hydroxyurea in Pediatric Patients with Sickle Cell Anemia; NCT01506544 and Single-Dose (SD) and Steady-State (SS) Pharmacokinetics of Hydroxyurea in Children and Adolescents with Sickle Cell Disease), plasma drug concentration vs. time profiles were evaluated with a model independent approach in the HCnew and HCchronic groups. Various predictive scenarios were analysed to evaluate whether systemic exposure with hydroxycarbamide could be accurately predicted. Results: Absorption of hydroxycarbamide was rapid, variable and dose independent. Dose-normalized peak plasma concentrations and drug exposure (AUC) were higher, and weight-normalized apparent oral clearance was lower in the HCnew group. We assessed a PK-guided dosing strategy along with other predictive scenarios and found that inclusion of plasma samples only slightly improved the accuracy of AUC predictions when compared to a population-based method. Conclusions: Children naïve to hydroxycarbamide exhibit a different PK profile compared to children receiving chronic therapy. Accuracy of population-based dosing is sufficient to target AUCs in individual patients. Further clearance/bioavailability studies are needed to address the factors responsible for variability in the disposition of hydroxycarbamide.

Original languageEnglish (US)
Pages (from-to)1478-1485
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume84
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Sickle Cell Anemia
Pharmacokinetics
Pharmaceutical Preparations
Area Under Curve
Hydroxyurea
Therapeutics
Population
Biological Availability
Multicenter Studies
Pediatrics
Weights and Measures

Keywords

  • children
  • hydroxycarbamide
  • pharmacokinetics
  • sickle cell disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Estepp, Jeremie H. ; Wiczling, Paweł ; Moen, Joseph ; Kang, Guolian ; Mack, Joana Marie ; Liem, Robert ; Panepinto, Julie A. ; Garg, Uttam ; Kearns, Gregory ; Neville, Kathleen A. / Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy : pharmacokinetics and predictive models for drug exposure. In: British Journal of Clinical Pharmacology. 2018 ; Vol. 84, No. 7. pp. 1478-1485.
@article{b35c3705650a4e0890d0d35545a4ee65,
title = "Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure",
abstract = "Aims: The purposes of this work were to: (1) compare pharmacokinetic (PK) parameters for hydroxycarbamide in children receiving their first dose (HCnew) vs. those receiving chronic therapy (HCchronic), (2) assess the external validity of a published PK dosing strategy, and (3) explore the accuracy of dosing strategies based on a limited number of HC measurements. Methods: Utilizing data from two prospective, multicenter trials of hydroxycarbamide (Pharmacokinetics of Liquid Hydroxyurea in Pediatric Patients with Sickle Cell Anemia; NCT01506544 and Single-Dose (SD) and Steady-State (SS) Pharmacokinetics of Hydroxyurea in Children and Adolescents with Sickle Cell Disease), plasma drug concentration vs. time profiles were evaluated with a model independent approach in the HCnew and HCchronic groups. Various predictive scenarios were analysed to evaluate whether systemic exposure with hydroxycarbamide could be accurately predicted. Results: Absorption of hydroxycarbamide was rapid, variable and dose independent. Dose-normalized peak plasma concentrations and drug exposure (AUC) were higher, and weight-normalized apparent oral clearance was lower in the HCnew group. We assessed a PK-guided dosing strategy along with other predictive scenarios and found that inclusion of plasma samples only slightly improved the accuracy of AUC predictions when compared to a population-based method. Conclusions: Children na{\"i}ve to hydroxycarbamide exhibit a different PK profile compared to children receiving chronic therapy. Accuracy of population-based dosing is sufficient to target AUCs in individual patients. Further clearance/bioavailability studies are needed to address the factors responsible for variability in the disposition of hydroxycarbamide.",
keywords = "children, hydroxycarbamide, pharmacokinetics, sickle cell disease",
author = "Estepp, {Jeremie H.} and Paweł Wiczling and Joseph Moen and Guolian Kang and Mack, {Joana Marie} and Robert Liem and Panepinto, {Julie A.} and Uttam Garg and Gregory Kearns and Neville, {Kathleen A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/bcp.13426",
language = "English (US)",
volume = "84",
pages = "1478--1485",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "7",

}

Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy : pharmacokinetics and predictive models for drug exposure. / Estepp, Jeremie H.; Wiczling, Paweł; Moen, Joseph; Kang, Guolian; Mack, Joana Marie; Liem, Robert; Panepinto, Julie A.; Garg, Uttam; Kearns, Gregory; Neville, Kathleen A.

In: British Journal of Clinical Pharmacology, Vol. 84, No. 7, 01.07.2018, p. 1478-1485.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy

T2 - pharmacokinetics and predictive models for drug exposure

AU - Estepp, Jeremie H.

AU - Wiczling, Paweł

AU - Moen, Joseph

AU - Kang, Guolian

AU - Mack, Joana Marie

AU - Liem, Robert

AU - Panepinto, Julie A.

AU - Garg, Uttam

AU - Kearns, Gregory

AU - Neville, Kathleen A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Aims: The purposes of this work were to: (1) compare pharmacokinetic (PK) parameters for hydroxycarbamide in children receiving their first dose (HCnew) vs. those receiving chronic therapy (HCchronic), (2) assess the external validity of a published PK dosing strategy, and (3) explore the accuracy of dosing strategies based on a limited number of HC measurements. Methods: Utilizing data from two prospective, multicenter trials of hydroxycarbamide (Pharmacokinetics of Liquid Hydroxyurea in Pediatric Patients with Sickle Cell Anemia; NCT01506544 and Single-Dose (SD) and Steady-State (SS) Pharmacokinetics of Hydroxyurea in Children and Adolescents with Sickle Cell Disease), plasma drug concentration vs. time profiles were evaluated with a model independent approach in the HCnew and HCchronic groups. Various predictive scenarios were analysed to evaluate whether systemic exposure with hydroxycarbamide could be accurately predicted. Results: Absorption of hydroxycarbamide was rapid, variable and dose independent. Dose-normalized peak plasma concentrations and drug exposure (AUC) were higher, and weight-normalized apparent oral clearance was lower in the HCnew group. We assessed a PK-guided dosing strategy along with other predictive scenarios and found that inclusion of plasma samples only slightly improved the accuracy of AUC predictions when compared to a population-based method. Conclusions: Children naïve to hydroxycarbamide exhibit a different PK profile compared to children receiving chronic therapy. Accuracy of population-based dosing is sufficient to target AUCs in individual patients. Further clearance/bioavailability studies are needed to address the factors responsible for variability in the disposition of hydroxycarbamide.

AB - Aims: The purposes of this work were to: (1) compare pharmacokinetic (PK) parameters for hydroxycarbamide in children receiving their first dose (HCnew) vs. those receiving chronic therapy (HCchronic), (2) assess the external validity of a published PK dosing strategy, and (3) explore the accuracy of dosing strategies based on a limited number of HC measurements. Methods: Utilizing data from two prospective, multicenter trials of hydroxycarbamide (Pharmacokinetics of Liquid Hydroxyurea in Pediatric Patients with Sickle Cell Anemia; NCT01506544 and Single-Dose (SD) and Steady-State (SS) Pharmacokinetics of Hydroxyurea in Children and Adolescents with Sickle Cell Disease), plasma drug concentration vs. time profiles were evaluated with a model independent approach in the HCnew and HCchronic groups. Various predictive scenarios were analysed to evaluate whether systemic exposure with hydroxycarbamide could be accurately predicted. Results: Absorption of hydroxycarbamide was rapid, variable and dose independent. Dose-normalized peak plasma concentrations and drug exposure (AUC) were higher, and weight-normalized apparent oral clearance was lower in the HCnew group. We assessed a PK-guided dosing strategy along with other predictive scenarios and found that inclusion of plasma samples only slightly improved the accuracy of AUC predictions when compared to a population-based method. Conclusions: Children naïve to hydroxycarbamide exhibit a different PK profile compared to children receiving chronic therapy. Accuracy of population-based dosing is sufficient to target AUCs in individual patients. Further clearance/bioavailability studies are needed to address the factors responsible for variability in the disposition of hydroxycarbamide.

KW - children

KW - hydroxycarbamide

KW - pharmacokinetics

KW - sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=85035214185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035214185&partnerID=8YFLogxK

U2 - 10.1111/bcp.13426

DO - 10.1111/bcp.13426

M3 - Article

C2 - 28884840

AN - SCOPUS:85035214185

VL - 84

SP - 1478

EP - 1485

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 7

ER -